Bayer Ag · XETR:BAYN
Bayer — Q1 2017 Earnings Presentation
11 slides from Bayer's earnings presentation, Apr 27, 2017
Slide 1: Investor Conference Call Q1 2017 Results
Investor Conference Call Q1 2017 Results April 27, 2017 / Werner Baumann, CEO
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual
Slide 3: Q1 2017 – Highlights
Q1 2017 – Highlights Strong start to the year for Bayer Growth momentum across all segments – very good business development at Pharma Key growth products at Pharma on track Significant increase in sales and earnings at Covestro Group outlook for FY 2017 raised, driven by Covestro performa
Slide 4: Q1 2017 – Strong Start to the Year
Q1 2017 – Strong Start to the Year Sales EBIT EBITDA Core EPS in € million before special items cont. operations % currency & portfolio adj. in € million in € million in € 13,244 3,893 11,854 3,116 3,387 2.62 2,320 2.35 Q1’16 Q1’17 Q1’16 Q1’17 Q1’16 Q1’17 Q1’16 Q1’17 +9% +34% +15% +11% Page 4 • Q1 2
Slide 5: Cash Flow And Net Financial Debt Development
Q1 2017 – Cash Flow And Net Financial Debt Development Cash Flow Net Financial Debt in € million, ∆% yoy Fx adj., continuing operations in € billion Operating EBITDA CapEx Cash Flow 11.8 -€1.4bn 10.4 3,846 826 415 ∆ y-o-y +14% +50% +14% Mar. 31, 2017 Dec. 31, 2016 Page 5 • Q1 2017 Investor Conferenc
Slide 6: Very Good Business Development at Pharmaceuticals
Q1 2017 – Very Good Business Development at Pharmaceuticals Sales Key Growth Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q1‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 4,263 +7% 751 +20% 1,502 +19% 3,889 1,261 446 +19% 100 +31% 75 +9% 73 +28% Q1‘16
Slide 7: Increase in Sales and Earnings at Consumer Health
Q1 2017 – Increase in Sales and Earnings at Consumer Health Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q1‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 1,601 +3% 1,520 383 392 +2% 274* +8% 190 -2% 102 +21% 95 +2% Q1‘16 Q1‘17 Sum 662 +5% Q1
Slide 8: Crop Science with Encouraging Performance in North America
Q1 2017 – Crop Science with Encouraging Performance in North America Sales Regions EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q1‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 3,120 +3% 2,936 Environm. 147 +21% 117 Science Seeds 722 +8% Europe / Middle East 6
Slide 9: Animal Health with Significant Earnings Growth
Q1 2017 – Animal Health with Significant Earnings Growth Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. Q1‘17 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 440 +3% 136 -10% 135 +11% 408 122 76 +38% 35 +6% 27 -6% Sum 274 +2% Q1‘16 Q1‘17 Q1‘16 Q1‘1
Slide 10: Group Outlook for FY 2017 Raised, Driven by Covestro Performance
Group Outlook for FY 2017 Raised, Driven by Covestro Performance Sales ∆ % yoy Fx and portfolio adj., EBITDA before special items ,Continuing operations Forecast 2017 2016 update April Change Sales Group €46.8bn Mid- to high-single-digit % increase to ~€51bn Life Sciences €34.9bn Mid-single-digit %
Slide 11: Investor Conference Call Q1 2017 Results
Investor Conference Call Q1 2017 Results April 27, 2017 / Werner Baumann, CEO